Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Monocytes infiltrate gliomas but differentiate into immunosuppressive macrophages, promoting tumor growth.
• Redirecting monocyte differentiation presents an underexplored therapeutic avenue for glioma.
• M1-polarized macrophage-derived extracellular vesicles (M1-EVs) can induce anti-tumor macrophage differentiation via TNF-α signaling.

Purpose of the Study:

• To engineer M1-EVs for enhanced glioma targeting and overcoming immune evasion.
• To develop a therapeutic platform for directing monocyte differentiation towards anti-tumor phenotypes in glioma.

Main Methods:

• M1-EVs were engineered with tumor-targeting chimeric antigen receptors (CARs) and CD47-blocking SIRPα variants, creating dual-targeting M1-CS-EVs.
• Assessed M1-CS-EVs for blood-brain barrier penetration, glioma accumulation, and CD47-SIRPα interaction disruption.
• Evaluated therapeutic efficacy in orthotopic glioma models, measuring anti-tumor immune response, phagocytosis, tumor growth suppression, and survival.

Main Results:

• Engineered M1-CS-EVs demonstrated improved blood-brain barrier penetration and glioma accumulation.
• M1-CS-EVs effectively disrupted CD47-SIRPα interactions, enhancing local anti-tumor immunity and phagocytosis.
• Treatment with M1-CS-EVs significantly suppressed glioma growth and prolonged survival in preclinical models.

Conclusions:

• Dual-targeting M1-CS-EVs represent a promising platform technology for glioma treatment.
• This strategy effectively redirects monocyte differentiation to anti-tumor phenotypes, overcoming key therapeutic challenges.
• The findings offer a broadly applicable approach for enhancing immunotherapy in glioma.